Eikon Therapeutics, Inc. announced the pricing of its upsized initial public offering of 21,177,600 shares of common stock at $18.00 per share, expecting gross proceeds of approximately $381 million. The common stock will trade on Nasdaq under the symbol “EIKN” starting February 5, 2026. The offering is set to close around February 6, 2026, managed by J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho. The registration statement on Form S-1 was declared effective on January 30, 2026. Eikon focuses on oncology, aiming to develop critical medicines for various cancers while also leveraging its technology platform and management team expertise.

Read more at GlobeNewswire: Eikon Therapeutics Announces Pricing of Upsized Initial